Literature DB >> 15115679

Differentiation of human umbilical cord blood CD133+ stem cells towards myelo-monocytic lineage.

Katharina Ruzicka1, Branka Grskovic, Vladimir Pavlovic, Durdi Qujeq, Alireza Karimi, Mathias M Mueller.   

Abstract

BACKGROUND: Characterisation of stem cells by flow cytometry, their expansion and differentiation are presently of major interest for cell engineering as the basis of a therapeutic concept for transplantation. Haematopoietic stem cells (HSC) express CD34, the adhesion structure which binds 2L-selectin, CD117, a receptor for stem cell factor (SCF; c-kit ligand), and CD133, a transmembrane protein belonging to the family of mucoproteins.
METHODS: The aim of the present investigation was the systematic investigation of proliferation and differentiation characteristics of umbilical cord blood stem cells (UCBSC) isolated by an immmunomagnetic separation system using CD133 antibody-coated microbeads and to evaluate the effects of different sera and various concentrations, as well as the effects of IL-3 and IL-6 on total cell expansion and differentiation of isolated CD133+ cells. Differentiation patterns were measured by flow cytometry.
RESULTS: After the immmunomagnetic separation the yield of CD133+ cells was 0.45+/-0.17 x 10(6) cells/ml; the purity of isolated CD133+ cells was 95.79+/-1.86%. The majority of CD133+ cells coexpressed CD117. The most pronounced expansion during cultivation of 2 weeks was achieved in media supplemented with 12.5% horse serum plus 12.5% fetal calf serum (FCS) with stem cell factor and interleukine 3; the fold-expansion was 16.67+/-6.20. During the cultivation period, UCBSC were constantly loosing stem cell markers and differentiated towards myelo-monocyte lineage (granulocytes and/or monocytes).
CONCLUSIONS: These in vitro results demonstrate that thorough investigation of various cultivation conditions is needed for successful expansion and differentiation of stem cells towards different lineages to be used therapeutically for replacement of damaged cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115679     DOI: 10.1016/j.cccn.2003.11.019

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.

Authors:  Matteo Brioschi; John Fischer; Roberto Cairoli; Stefano Rossetti; Laura Pezzetti; Michele Nichelatti; Mauro Turrini; Francesca Corlazzoli; Barbara Scarpati; Enrica Morra; Nicoletta Sacchi; Alessandro Beghini
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  Identification of CD13+CD36+ cells as a common progenitor for erythroid and myeloid lineages in human bone marrow.

Authors:  Ling Chen; Zhigang Gao; Jianqiong Zhu; Griffin P Rodgers
Journal:  Exp Hematol       Date:  2007-07       Impact factor: 3.084

3.  Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease.

Authors:  Chi-Chao Chan; Emily Y Chew; Defen Shen; Joseph Hackett; Zhengping Zhuang
Journal:  Mol Vis       Date:  2005-09-01       Impact factor: 2.367

4.  Osteocalcin positive CD133+/CD34-/KDR+ progenitor cells as an independent marker for unstable atherosclerosis.

Authors:  Andreas J Flammer; Mario Gössl; Robert Jay Widmer; Martin Reriani; Ryan Lennon; Darrell Loeffler; Sarah Shonyo; Robert D Simari; Lilach O Lerman; Sundeep Khosla; Amir Lerman
Journal:  Eur Heart J       Date:  2012-07-31       Impact factor: 29.983

5.  Characteristics of hematopoietic stem cells of umbilical cord blood.

Authors:  Anna Hordyjewska; Łukasz Popiołek; Anna Horecka
Journal:  Cytotechnology       Date:  2014-11-06       Impact factor: 2.058

Review 6.  Contribution of human hematopoietic stem cells to liver repair.

Authors:  Ping Zhou; Louisa Wirthlin; Jeannine McGee; Geralyn Annett; Jan Nolta
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.